logo

Adamas Pharmaceuticals Inc (ADMS)



Trade ADMS now with
  Date
  Headline
2/24/2021 9:25:02 PM Adamas Pharma Announces Pricing Of Follow-on Public Offering Of 12.50 Mln At $4.40/shr
2/1/2021 8:06:56 AM Adamas Enters Settlement Of Patent Litigation With Zydus
12/2/2020 6:51:50 AM Adamas Signs Agreement To Settle Its Ongoing Patent Litigation With Osmotica
9/11/2020 9:33:58 AM Adamas Presents New Post-hoc Data Analysis For GOCOVRI In Parkinson’s Disease Patients With Dyskinesia
9/13/2019 7:34:18 AM Adamas Pharma Appoints Neil McFarlane As CEO
4/19/2018 5:35:44 AM Adamas Announces Final Results From Phase 3 Open-Label Study Of GOCOVRI In Parkinson’s Disease Patients With Dyskinesia
4/3/2018 9:25:50 AM Adamas Says First Patient Enrolled In Pivotal Phase 3 Clinical Trial Of ADS-5102
2/19/2018 8:03:23 PM Adamas Announces Declaratory Judgment Action Filed By Osmotica Related To Approved OSMOLEX ER
1/23/2018 8:51:36 PM Adamas Pharma Prices Public Offering Of 3 Mln Shares At $41.50/shr
1/22/2018 4:04:06 PM Adamas Pharma Announces Proposed Public Offering Of $85 Mln Of Common Stock